Podcasts

Dr Vale discusses data from a phase 2 trial evaluating blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Drs Camidge and Reed chronicle Dr Reed’s experience-rich career, recognizing the motivations and people at each stop that made his success possible.

Drs Tiesi, Scholer, and Pletcher discuss the growing role for TAMP as a regional therapy strategy for patients with locally advanced PDAC.

Sonali Smith, MD, discusses CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults.

Drs McCann and Nunnery share their stories and perspectives as leading women in oncology in honor of International Women's Day.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of daratumumab plus VRd for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

Eric K. Singhi, MD, discusses where TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan may fit in evolving treatment algorithms in lung cancer.

Drs Camidge and Clackson discussed Dr Clackson’s career journey through the biotechnology field, which began with a curiosity about biology and evolution.

Anne Chiang, MD, PhD, discusses the rapidly evolving treatment landscape in SCLC and what this new era of innovation means for patients.

Drs Kruse and O’Brien highlight the various roles of imaging modalities in breast cancer diagnosis and treatment decision-making.

David Carbone, MD, PhD, discusses the 6-year data from the phase 3 CheckMate 9LA trial (NCT03215706).

Dr Sammons discusses the rationale for and findings from a phase 2 study evaluating pumitamig in patients with locally advanced or metastatic TNBC.

Rashmi Chugh, MD, discusses the ongoing development of the investigational γ-secretase inhibitor varegacestat for patients with desmoid tumors.

Drs Matulonis and Campos discuss the evolving landscape of newly diagnosed cervical cancer, from epidemiologic trends to emerging therapeutic strategies.

Rachna T. Shroff, MD, MS, FASCO, and Kristen Spencer, DO, discuss factors weighed when navigating first-line chemotherapy selection in pancreatic cancer.

Drs Armstrong and Tawagi highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium in prostate, bladder, and kidney cancers.

Girindra Raval, MD, and Hossein Borghaei, DO, MS, discuss Borghaei’s personal journey into medicine and oncology.

Philippos Costa, MD, and Hari Deshpande, MD, answer common questions about chondrosarcoma staging, diagnosis, surgery, and future research avenues.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses the FDA approval of subcutaneous amivantamab for patients with EGFR-mutated NSCLC.

Drs Camidge and Kantor reflect on Dr Kantor's decades-long career in oncology, which was propelled by a devotion to patients.